Skip to main content
. 2013 Jan 7;14(1):161–175. doi: 10.1120/jacmp.v14i1.4035

Figure 2.

Figure 2

Representative DVHs of 2 Group A patients with lumpectomy cavities in the inner (a) and outer (b) quadrants. For the inner case (a), ipsilateral lung V10% was 23.7% and contralateral breast maximum dose was 6.9% with RapidArc, which exceeded the RAPID trail dose constraint. For the outer breast lesion (b), all the RAPID/NASBP‐B39 RTOG0413 trials dose constraints were met; however, CG‐Darc and RapidArc further reduced the ipsilateral breast overall dose as compared with 3D CRT.